Chandrasekaran E V, Chawda Ram, Rhodes John M, Locke Robert D, Piskorz Conrad F, Matta Khushi L
Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Carbohydr Res. 2003 Apr 22;338(9):887-901. doi: 10.1016/s0008-6215(03)00021-1.
Human colon carcinoma cell fucosyltransferase (FT) in contrast to the FTs of several human cancer cell lines, utilized GlcNAcbeta1,4GlcNAcbeta-O-Bn as an acceptor, the product being resistant to alpha1,6-L-Fucosidase and its formation being completely inhibited by LacNAc Type 2 acceptors. Further, this enzyme was twofold active towards the asialo agalacto glycopeptide as compared to the parent asialoglycopeptide. Only 60% of the GlcNAc moieties were released from [14C]fucosylated asialo agalacto triantennary glycopeptide by jack bean beta-N-acetylhexosaminidase. These alpha1,3-L-fucosylating activities on multiterminal GlcNAc residues and chitobiose were further examined by characterizing the products arising from fetuin triantennary and bovine IgG diantennary glycopeptides and their exoglycosidase-modified derivatives using lectin affinity chromatography. Utilization of [14C]fucosylated glycopeptides with cloned FTs indicated that Lens culinaris lectin and Aleuria aurantia lectin (AAL) required, respectively, the diantennary backbone and the chitobiose core alpha1,6-fucosyl residue for binding. The outer core alpha1,3- but not the alpha-1,2-fucosyl residues decreased the binding affinity of AAL. The AAL-binding fraction from [14C]fucosylated asialo fetuin, using colon carcinoma cell extract, contained 60% Endo F/PNGaseF resistant chains. Similarly AAL-binding species from [14C]fucosylated TFA-treated bovine IgG using colon carcinoma cell extract showed significant resistance to endo F/PNGaseF. However, no such resistance was found with the corresponding AAL non- and weak-binding species. Thus colon carcinoma cells have the capacity to fucosylate the chitobiose core in glycoproteins, and this alpha1,3-L-fucosylation is apparently responsible for the AAL binding of glycoproteins. A cloned FT VI was found to be very similar to this enzyme in acceptor substrate specificities. The colon cancer cell FT thus exhibits four catalytic roles, i.e., alpha1,3-L-fucosylation of: (a) Galbeta1,4GlcNAcbeta-; (b) multiterminal GlcNAc units in complex type chain; (c) the inner core chitobiose of glycopeptides and glycoproteins; and (d) the nonreducing terminal chiotobiose unit.
与几种人类癌细胞系的岩藻糖基转移酶(FT)不同,人结肠癌细胞岩藻糖基转移酶利用GlcNAcbeta1,4GlcNAcbeta - O - Bn作为受体,产物对α1,6 - L - 岩藻糖苷酶具有抗性,且其形成完全被2型乳糖胺受体抑制。此外,与亲本去唾液酸糖肽相比,该酶对去唾液酸去半乳糖糖肽的活性高两倍。用刀豆β - N - 乙酰己糖胺酶从[14C]岩藻糖基化的去唾液酸去半乳糖三触角糖肽中仅释放出60%的GlcNAc部分。通过使用凝集素亲和色谱法表征来自胎球蛋白三触角和牛IgG二触角糖肽及其外切糖苷酶修饰衍生物产生的产物,进一步研究了多末端GlcNAc残基和壳二糖上的这些α1,3 - L - 岩藻糖基化活性。用克隆的FTs对[14C]岩藻糖基化糖肽的利用表明,扁豆凝集素和橙黄银耳凝集素(AAL)分别需要二触角主链和壳二糖核心α1,6 - 岩藻糖基残基进行结合。外核心α1,3 - 而非α - 1,2 - 岩藻糖基残基降低了AAL的结合亲和力。使用结肠癌细胞提取物从[14C]岩藻糖基化的去唾液酸胎球蛋白中获得的AAL结合部分含有60%耐内切糖苷酶F/肽 - N - 聚糖酶F的链。同样,使用结肠癌细胞提取物从[14C]岩藻糖基化的三氟乙酸处理的牛IgG中获得的AAL结合物种对内切糖苷酶F/肽 - N - 聚糖酶F具有显著抗性。然而,在相应的AAL非结合和弱结合物种中未发现这种抗性。因此,结肠癌细胞具有对糖蛋白中的壳二糖核心进行岩藻糖基化的能力,并且这种α1,3 - L - 岩藻糖基化显然是糖蛋白与AAL结合的原因。发现克隆的FT VI在受体底物特异性方面与该酶非常相似。因此,结肠癌细胞FT表现出四种催化作用,即对以下物质的α1,3 - L - 岩藻糖基化:(a)Galbeta1,4GlcNAcbeta -;(b)复合类型链中的多末端GlcNAc单元;(c)糖肽和糖蛋白的内核壳二糖;以及(d)非还原末端壳二糖单元。